Deltec Asset Management LLC trimmed its holdings in Ocular Therapeutix Inc (NASDAQ:OCUL) by 30.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 214,239 shares of the biopharmaceutical company’s stock after selling 95,468 shares during the quarter. Deltec Asset Management LLC’s holdings in Ocular Therapeutix were worth $953,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in OCUL. TIAA CREF Investment Management LLC grew its position in Ocular Therapeutix by 0.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 111,019 shares of the biopharmaceutical company’s stock valued at $1,029,000 after buying an additional 785 shares during the last quarter. Nationwide Fund Advisors raised its stake in Ocular Therapeutix by 10.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,344 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 1,204 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Ocular Therapeutix by 4.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 33,417 shares of the biopharmaceutical company’s stock valued at $310,000 after purchasing an additional 1,422 shares during the last quarter. Teachers Advisors LLC raised its stake in Ocular Therapeutix by 6.2% in the 2nd quarter. Teachers Advisors LLC now owns 42,679 shares of the biopharmaceutical company’s stock valued at $396,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Ocular Therapeutix by 0.4% in the 2nd quarter. Vanguard Group Inc. now owns 905,456 shares of the biopharmaceutical company’s stock valued at $8,394,000 after purchasing an additional 3,194 shares during the last quarter. 43.30% of the stock is currently owned by institutional investors and hedge funds.
In other Ocular Therapeutix news, insider Daniel M. Bollag acquired 24,700 shares of the firm’s stock in a transaction on Wednesday, December 6th. The stock was purchased at an average cost of $3.93 per share, for a total transaction of $97,071.00. Following the transaction, the insider now owns 24,700 shares of the company’s stock, valued at approximately $97,071. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Antony C. Mattessich acquired 21,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were acquired at an average price of $4.29 per share, with a total value of $90,090.00. Following the completion of the transaction, the insider now directly owns 21,000 shares in the company, valued at approximately $90,090. The disclosure for this purchase can be found here. Insiders purchased a total of 69,500 shares of company stock valued at $304,781 in the last quarter. 26.10% of the stock is currently owned by corporate insiders.
Several brokerages recently weighed in on OCUL. Guggenheim began coverage on shares of Ocular Therapeutix in a research note on Monday, October 23rd. They issued a “buy” rating and a $12.00 target price for the company. ValuEngine raised Ocular Therapeutix from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Zacks Investment Research raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Ocular Therapeutix in a research note on Wednesday, November 8th. Finally, BTIG Research raised Ocular Therapeutix from a “neutral” rating to a “buy” rating in a research note on Friday, January 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $20.67.
Shares of Ocular Therapeutix Inc (OCUL) traded down $0.18 during mid-day trading on Monday, reaching $5.00. The company had a trading volume of 250,762 shares, compared to its average volume of 599,865. Ocular Therapeutix Inc has a fifty-two week low of $3.30 and a fifty-two week high of $11.79. The company has a market capitalization of $149.06, a PE ratio of -2.26 and a beta of 1.53. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.79 and a quick ratio of 4.78.
Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.54). Ocular Therapeutix had a negative return on equity of 126.31% and a negative net margin of 3,241.19%. The business had revenue of $523.00 million during the quarter, compared to analysts’ expectations of $0.52 million. During the same quarter last year, the business posted ($0.39) earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. sell-side analysts expect that Ocular Therapeutix Inc will post -2.31 EPS for the current year.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix Inc (NASDAQ:OCUL).
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.